Comparative Evaluation of the Effectiveness of Tamsulosin and Silodosin in Patients with Benign Prostatic Hyperplasia and Diabetes Mellitus
DOI:
https://doi.org/10.31149/ijimm.v4i2.2696Keywords:
benign prostatic hyperplasia, diabetes mellitus, tamsulosin, silodosin, lower urinary tract symptoms, IPSSAbstract
The aim of the study was to conduct a comparative evaluation of the clinical efficacy and safety of the α1-adrenergic blockers tamsulosin and silodosin in patients with benign prostatic hyperplasia (BPH) associated with type 2 diabetes mellitus. The study included 40 patients over 60 years of age. Urodynamic parameters, the severity of lower urinary tract symptoms (LUTS), IPSS score, the frequency of adverse effects, and the impact of the drugs on blood pressure were assessed.
References
[1] EAU Guidelines on Management of Non-Neurogenic Male LUTS (including BPH). European Association of Urology. Arnhem, The Netherlands; 2025.
[2] Oelke M., Bachmann A., Descazeaud A., Emberton M., Gravas S., Michel M.C., et al. EAU Guidelines on Benign Prostatic Hyperplasia (BPH). Eur Urol. 2013;64(4):754–62.
[3] Chapple C., Roehrborn C.G. A systematic review of the efficacy and tolerability of selective α1-blockers in male lower urinary tract symptoms. Urology. 2006;68(2): 123–31.
[4] Kaplan S.A., Te A.E., Pressler L., Blaivas J., Botto H., Andersson K.-E., et al. Clinical outcomes of selective α1A-adrenoceptor blockade in men with LUTS/BPH. J Urol. 2011;186(4): 1285–93.
[5] Djavan B., Marberger M. Silodosin in the treatment of LUTS/BPH: a review of efficacy and safety. Int J Clin Pract. 2009;63(9): 1329–40.
[6] Gacci M., Salvi M., Sebastianelli A., De Nunzio C., Tubaro A., Vignozzi L. Efficacy and safety of silodosin in men with LUTS/BPH: a systematic review and meta-analysis. Clin Genitourin Cancer. 2014;12(3): 191–201.
[7] Roehrborn C.G., Siami P., Barkin J., Damião R., Major-Walker K., Nandy I., et al. Efficacy and safety of tamsulosin once daily in men with LUTS/BPH: results of the CombAT study. BJU Int. 2008;101(7): 864–874.
[8] Chapple C.R., Roehrborn C.G., Aizawa N., et al. Safety and efficacy of tamsulosin and silodosin for LUTS/BPH: a randomized comparative study. BMC Urol. 2017;17: 29.
[9] Emberton M., Andriole G., de la Rosette J., et al. Impact of α1-blockers on blood pressure and cardiovascular safety in patients with BPH. World J Urol. 2015;33(6): 817–829.
[10] Diabetes mellitus: management of lower urinary tract symptoms/neurogenic bladder. In: Standards of Medical Care in Diabetes—2025. American Diabetes Association. Diabetes Care. 2025;48(Suppl. 1):S187–S197..
[11] Abrams P., Andersson K.-E., Artibani W., et al. Evaluation and treatment of lower urinary tract symptoms in the ageing male: a consultation on current concepts and future priorities. Eur Urol. 2020;78(3): 344–358..
[12] McVary K.T., Roehrborn C.G., Avins A., et al. Update on AUA guideline on management of benign prostatic hyperplasia. J Urol. 2011;185(5): 1793–1803.
